vs

Side-by-side financial comparison of ACV Auctions Inc. (ACVA) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

ACV Auctions Inc. is the larger business by last-quarter revenue ($183.6M vs $151.7M, roughly 1.2× Tarsus Pharmaceuticals, Inc.). On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 15.1%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-14.7M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 12.3%).

ACV Auctions Inc. operates a leading digital wholesale vehicle auction platform serving automotive dealers across the U.S. and Canada. It offers end-to-end services including transparent vehicle inspections, secure payment processing, and logistics support, enabling efficient trading of used vehicles between registered wholesale buyers and sellers.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

ACVA vs TARS — Head-to-Head

Bigger by revenue
ACVA
ACVA
1.2× larger
ACVA
$183.6M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+113.3% gap
TARS
128.4%
15.1%
ACVA
More free cash flow
TARS
TARS
$27.6M more FCF
TARS
$13.0M
$-14.7M
ACVA
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
12.3%
ACVA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACVA
ACVA
TARS
TARS
Revenue
$183.6M
$151.7M
Net Profit
$-8.4M
Gross Margin
Operating Margin
-9.7%
-5.3%
Net Margin
-5.5%
Revenue YoY
15.1%
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$-0.12
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACVA
ACVA
TARS
TARS
Q4 25
$183.6M
$151.7M
Q3 25
$199.6M
$118.7M
Q2 25
$193.7M
$102.7M
Q1 25
$182.7M
$78.3M
Q4 24
$159.5M
$66.4M
Q3 24
$171.3M
$48.1M
Q2 24
$160.6M
$40.8M
Q1 24
$145.7M
$27.6M
Net Profit
ACVA
ACVA
TARS
TARS
Q4 25
$-8.4M
Q3 25
$-24.5M
$-12.6M
Q2 25
$-7.3M
$-20.3M
Q1 25
$-14.8M
$-25.1M
Q4 24
$-23.1M
Q3 24
$-16.0M
$-23.4M
Q2 24
$-17.1M
$-33.3M
Q1 24
$-20.5M
$-35.7M
Operating Margin
ACVA
ACVA
TARS
TARS
Q4 25
-9.7%
-5.3%
Q3 25
-11.9%
-12.2%
Q2 25
-3.7%
-21.6%
Q1 25
-7.9%
-33.5%
Q4 24
-16.2%
-36.8%
Q3 24
-10.0%
-52.3%
Q2 24
-11.6%
-81.6%
Q1 24
-15.5%
-136.5%
Net Margin
ACVA
ACVA
TARS
TARS
Q4 25
-5.5%
Q3 25
-12.3%
-10.6%
Q2 25
-3.8%
-19.8%
Q1 25
-8.1%
-32.1%
Q4 24
-34.8%
Q3 24
-9.4%
-48.7%
Q2 24
-10.6%
-81.6%
Q1 24
-14.1%
-129.4%
EPS (diluted)
ACVA
ACVA
TARS
TARS
Q4 25
$-0.12
$-0.17
Q3 25
$-0.14
$-0.30
Q2 25
$-0.04
$-0.48
Q1 25
$-0.09
$-0.64
Q4 24
$-0.15
$-0.57
Q3 24
$-0.10
$-0.61
Q2 24
$-0.10
$-0.88
Q1 24
$-0.13
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACVA
ACVA
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$271.5M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$429.7M
$343.4M
Total Assets
$1.1B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACVA
ACVA
TARS
TARS
Q4 25
$271.5M
$417.3M
Q3 25
$265.3M
$401.8M
Q2 25
$258.4M
$381.1M
Q1 25
$291.9M
$407.9M
Q4 24
$224.1M
$291.4M
Q3 24
$252.5M
$317.0M
Q2 24
$215.0M
$323.6M
Q1 24
$209.8M
$298.5M
Total Debt
ACVA
ACVA
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
ACVA
ACVA
TARS
TARS
Q4 25
$429.7M
$343.4M
Q3 25
$434.4M
$335.1M
Q2 25
$448.8M
$332.6M
Q1 25
$439.6M
$342.5M
Q4 24
$440.0M
$224.5M
Q3 24
$456.2M
$237.5M
Q2 24
$457.6M
$252.2M
Q1 24
$458.3M
$275.2M
Total Assets
ACVA
ACVA
TARS
TARS
Q4 25
$1.1B
$562.2M
Q3 25
$1.2B
$534.6M
Q2 25
$1.1B
$495.0M
Q1 25
$1.2B
$500.8M
Q4 24
$984.1M
$377.0M
Q3 24
$1.0B
$376.3M
Q2 24
$1.0B
$376.8M
Q1 24
$1.0B
$349.3M
Debt / Equity
ACVA
ACVA
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACVA
ACVA
TARS
TARS
Operating Cash FlowLast quarter
$-12.4M
$19.3M
Free Cash FlowOCF − Capex
$-14.7M
$13.0M
FCF MarginFCF / Revenue
-8.0%
8.6%
Capex IntensityCapex / Revenue
1.2%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$69.1M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACVA
ACVA
TARS
TARS
Q4 25
$-12.4M
$19.3M
Q3 25
$10.3M
$18.3M
Q2 25
$13.7M
$-29.4M
Q1 25
$66.6M
$-20.7M
Q4 24
$-3.2M
$-22.2M
Q3 24
$21.1M
$-8.7M
Q2 24
$4.5M
$-14.4M
Q1 24
$43.0M
$-37.8M
Free Cash Flow
ACVA
ACVA
TARS
TARS
Q4 25
$-14.7M
$13.0M
Q3 25
$7.7M
$16.3M
Q2 25
$10.9M
$-30.4M
Q1 25
$65.3M
$-21.2M
Q4 24
$-3.9M
$-22.3M
Q3 24
$20.2M
$-8.9M
Q2 24
$2.7M
$-15.4M
Q1 24
$41.9M
$-38.0M
FCF Margin
ACVA
ACVA
TARS
TARS
Q4 25
-8.0%
8.6%
Q3 25
3.8%
13.8%
Q2 25
5.6%
-29.6%
Q1 25
35.7%
-27.1%
Q4 24
-2.5%
-33.5%
Q3 24
11.8%
-18.6%
Q2 24
1.7%
-37.8%
Q1 24
28.8%
-137.5%
Capex Intensity
ACVA
ACVA
TARS
TARS
Q4 25
1.2%
4.2%
Q3 25
1.3%
1.6%
Q2 25
1.5%
1.0%
Q1 25
0.7%
0.8%
Q4 24
0.4%
0.1%
Q3 24
0.6%
0.6%
Q2 24
1.1%
2.5%
Q1 24
0.7%
0.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACVA
ACVA

Auction Marketplace Revenue$77.6M42%
Other Marketplace Revenue$72.4M39%
Customer Assurance$24.1M13%
Data Services Revenue$9.4M5%

TARS
TARS

Segment breakdown not available.

Related Comparisons